Aortic valve endocarditis in patients with bicuspid and tricuspid aortic valves

Tan Le, BS,a Nathan J. Graham, BS,b Aroma Naeem, BA,a Jeffrey Clemence, Jr, BS,a Juan Caceres, BS,b Xiaoting Wu, PhD,a Himanshu J. Patel, MD,a Karen M. Kim, MD,a G. Michael Deeb, MD,a and Bo Yang, MD, PhDa

ABSTRACT

Objective: To determine the long-term survival and rate of reoperation after surgical treatment of infective endocarditis (IE) in patients with a bicuspid aortic valve (BAV) and patients with a tricuspid aortic valve (TAV).

Methods: Between 1997 and 2017, 210 patients underwent surgical treatment for native aortic valve endocarditis, including 51 patients with BAV (24%) and 159 patients with TAV (76%). Data were obtained from the Society of Thoracic Surgeons data warehouse and hospital medical record review, supplemented with surveys and national death index data for more complete follow-up.

Results: Compared with the TAV IE group, the BAV IE group was significantly younger (42 years vs 54 years) and had lower incidence rates of hypertension, coronary artery disease, and congestive heart failure (CHF). There were no significant between-group differences in postoperative stroke, sepsis, pacemaker requirement, or in-hospital mortality (2.0% vs 4.4%). Liver disease was a risk factor for operative mortality (odds ratio [OR], 13; 95% CI, 3.3-30; P = .0002). The 10-year survival rate was 64% for the BAV group versus 46% for the TAV group (P = .0191). Significant risk factors for long-term mortality were intravenous drug use (hazard ratio [HR], 4.5; P < .0001), preoperative renal failure requiring dialysis (HR, 4.13; P < .0001), CHF (HR, 1.7; P = .04), and liver disease (HR, 2.6; P = .02). The HR for BAV was 0.67 (95% confidence interval [CI], 0.3-1.4). The 10-year postoperative cumulative incidence of reoperation was significantly higher in the BAV patients compared with the TAV patients (5.7% vs 4.5%; P = .045) with an HR of 2.4 (95% CI, 0.8-7.1; P = .11) for BAV.

Conclusions: BAV patients develop IE requiring surgery at a younger age than TAV patients, but have significantly better long-term survival. Early detection of BAV is important to prevent IE and provide aggressive surgical treatment should IE occur. (JTCVS Open 2021;8:228-36)

CENTRAL MESSAGE

Compared with patients with a tricuspid aortic valve, patients with a bicuspid aortic valve are at increased risk of developing endocarditis at a younger age but demonstrate better long-term survival after surgical treatment.

PERSPECTIVE

Compared with patients with a tricuspid aortic valve (TAV), those with a bicuspid aortic valve (BAV) are at increased risk of developing infective endocarditis (IE) at a younger age owing to intrinsic factors of the aortic valve, but have superior long-term survival. It is important to BAV early to provide recommendations for prevention of BAV endocarditis and to provide aggressive surgical treatment if IE occurs.

See Commentaries on pages 237 and 239.

Video clip is available online.

From the aDepartment of Cardiac Surgery, Michigan Medicine, Ann Arbor, Mich; and bUniversity of Michigan Medical School, Ann Arbor, Mich. Dr Yang is supported by the National Heart, Lung, and Blood Institute (Grants K08 HL130614, R01 HL141891, and R01 HL151776), the Phil Jenkins Breakthrough Fund, and the Darlene and Stephen J. Szatmari Fund. A. Le, N. Graham, and A. Naeem contributed equally as co-first authors. Received for publication Sept 2, 2021; accepted for publication Sept 3, 2021; available ahead of print Sept 25, 2021.

Address for reprints: Bo Yang, MD, PhD, 5155 Frankel Cardiovascular Center, 1500 East Medical Center Dr, Ann Arbor, MI 48109 (E-mail: boya@med.umich.edu). 2666-2736

Copyright © 2021 The Author(s). Published by Elsevier Inc. on behalf of The American Association for Thoracic Surgery. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). https://doi.org/10.1016/j.xjon.2021.09.007

228 JTCVS Open • December 2021
Patients with bicuspid aortic valve (BAV) develop infective endocarditis (IE) at significantly higher rates than the general population. According to an analysis of selected case series, 10% to 30% of patients with BAV develop IE, and 25% of all IE cases develop in patients with BAV. In a longitudinal population-based study of the total burden of IE in patients with BAV, Michelen and colleagues reported an 17-fold higher incidence of IE in patients with native BAV compared with the general population. Patients with BAV IE also experienced significant morbidity, with 67% requiring surgical treatment and a mortality rate of 22%. Despite the known risks of IE developing in patients with BAV and significant operative morbidity and mortality, long-term outcomes related to IE in this population have not been well studied. Data for population-based cohorts of patients with BAV IE and TAV IE with longitudinal follow-up is still lacking. Thus, we conducted this study to compare short-term and long-term morbidity and mortality outcomes after surgical treatment of IE in patients with BAV compared with patients with TAV and provide evidence to guide the management of IE in patients with BAV.

**METHODS**

This study was approved by the Institutional Review Board at the University of Michigan (HUM00142927; 2018) and a waiver of informed consent was obtained.

**Patient Selection**

Between 1997 and 2017, 210 patients with native aortic valve IE underwent surgery for aortic valve replacement (AVR) or root replacement at the University of Michigan. Patients were divided into 2 groups based on the presence of a BAV (n = 51) or TAV (n = 159). Patients with prosthetic valve endocarditis were excluded, because we were studying aortic valve IE in native BAV and TAV. The Society of Thoracic Surgeons data warehouse was used to identify the relevant cohort and to determine the preoperative variables. These data were supplemented by medical chart review for specified variables. Survival and reoperation data were collected by medical record review and supplemented with surveys (including letters and phone calls) and National Death Index data through December 31, 2018, the study’s end date. Completeness of follow-ups for death and reoperation were calculated based on the ratio of the observed person-time and potential person-time follow-up.

**TABLE 1. Preoperative and demographic data**

| Variable                                      | TAV group (N = 159) | BAV group (N = 51) | P value |
|------------------------------------------------|---------------------|--------------------|---------|
| Age, y, median (IQR)                           | 54 (44-65)          | 42 (30-56)         | <.0001  |
| Female sex, n (%)                              | 42 (26)             | 7 (14)             | .062    |
| Coronary artery disease, n (%)                 | 35 (22)             | 5 (9.8)            | .053    |
| Diabetes, n (%)                                | 31 (20)             | 9 (18)             | .770    |
| Dyslipidemia, n (%)                            | 46 (29)             | 14 (27)            | .839    |
| Hypertension, n (%)                            | 92 (58)             | 20 (39)            | .020    |
| Current smoker, n (%)                          | 34 (21)             | 15 (29)            | .238    |
| Lung disease, n (%)                            | 16 (10)             | 5 (9.8)            | .957    |
| Invasive drug use, n (%)                       | 25 (16)             | 4 (7.8)            | .156    |
| Depression, n (%)                              | 18 (11)             | 4 (7.8)            | .480    |
| Alcohol use (>8 drinks/wk), n (%)              | 12 (4.4)            | 4 (7.8)            | .468    |
| Liver disease, n (%)                           | 15 (9.4)            | 7 (14)             | .384    |
| Previous myocardial infarction, n (%)          | 28 (18)             | 7 (14)             | .517    |
| Congestive heart failure, n (%)                | 94 (59)             | 21 (41)            | .025    |
| Stroke, n (%)                                  | 29 (18)             | 12 (24)            | .406    |
| Sepsis, n (%)                                  | 30 (19)             | 6 (12)             | .242    |
| Cardiogenic shock, n (%)                       | 14 (8.8)            | 6 (12)             | .585    |
| Arrhythmia, n (%)                              | 17 (11)             | 3 (5.9)            | .416    |
| Previous cardiac surgery, n (%)                | 15 (10)             | 3 (5.9)            | .150    |

Significant P values are in bold type. TAV: Tricuspid aortic valve; BAV: bicuspid aortic valve; IQR, interquartile range; CABG, coronary artery bypass grafting. *Based on retrospective chart review in patients with documented sepsis in the context of a suspected or proven infection via blood cultures and a systemic inflammatory response syndrome.

In the study, the median follow-up was calculated as the median time from the date of surgery to when the patient was last known to be alive or experienced an event.
Operative Technique

In patients with infected aortic valves that could not be repaired, AVR was performed. Three types of prostheses were used: bioprosthesis (stented and stentless valves), homografts, and mechanical valves. Before early 2000, we used homografts; we later switched to stentless valves for their accessibility and lower cost, and also used stented valves when appropriate. Mechanical valves were used in younger patients. We reported the detailed surgical technique previously.5 In brief, radical debridement of infected tissue was essential in preparation for valve implantation. In patients without root abscess, the infected leaflets were removed and the root was extensively debrided of any necrotic tissue. Any defect of the aortic root was patched with autologous pericardium or bovine pericardium if necessary. Routine AVR was completed with a prosthesis.

In patients with root abscess, if the cavity involved less than one-third (1 sinus) of the aortic annulus, the cavity was patched with autologous pericardium or bovine pericardium if necessary. Routine AVR was completed with a prosthesis.

In patients with root abscess, if the cavity involved less than one-third (1 sinus) of the aortic annulus, the cavity was patched with autologous pericardium or bovine pericardium followed by the AVR. If the abscess involved more than one-third (2 sinuses) of the aortic annulus, then either a total root replacement with separate reimplantation of the 2 coronary buttons or patch repair of the cavity and modified inclusion aortic root repair was completed. Stentless valves, homografts, and mechanical valve composite valve grafts were used for total root replacement. For patients with root abscess and with a destroyed aortomitral curtain, we directly anastomosed the stentless valve or homograft to the mitral valve annulus and muscular septum after extensive debridement and then reimplanted the 2 coronary buttons.

Statistical Analysis

Continuous data are presented as median (interquartile range [IQR]), and categorical data are presented as number (%). Univariate comparisons between groups were performed using the χ² test for categorical data. The Kolmogorov–Smirnov D test and Cramer–von Mises tests were used to test the normality of the data. The Wilcoxon rank-sum test was performed for continuous data. Univariable logistic regression was used to calculate the odds ratio (OR) of risk factors for operative mortality, including BAV, liver disease, and emergent status. Survival curves were estimated using the Kaplan–Meier method with the log-rank test to test the significance of survival differences. The Cox proportional hazards regression model was used to calculate the adjusted hazard ratios (HRs) for mortality since surgery, adjusting for group, age (modeled as a binary variable owing to violation of the proportional hazards assumption), sex, history of intravenous (IV) drug use, coronary artery disease, cardiogenic shock, congestive heart failure, preoperative sepsis, preoperative liver disease, and preoperative renal failure requiring dialysis. The variables entered into the logistic model and Cox model were chosen to identify the independent risk factors and were based on variables used in previous reports in the literature and in clinical practice. We examined the proportional hazards assumption using supremum tests for martingale residuals. \( P < .05 \) was considered to indicate statistical significance. Cumulative incidence function curves were adjusted for death as a competing risk using a cause-specific model to assess the incidence of reoperation after surgery. Gray’s test was used to assess whether the difference in the cumulative incidence function curves between groups was significant. Statistical analyses were performed with SAS (SAS Institute, Cary, NC).

RESULTS

Demographic and Preoperative Results

The 2 groups shared similar demographics for the majority of categories. One difference between the groups was in age of onset of IE; patients with BAV presented with IE at a
TABLE 2. Operative data

| Variable                                | TAV group (N = 159) | BAV group (N = 51) | P value |
|-----------------------------------------|---------------------|--------------------|---------|
| Causative microorganism, n (%)          |                     |                    | .001    |
| Staphylococci                           | 51 (32)             | 14 (27)            | .534    |
| *Staphylococcus aureus*                 | 32 (20)             | 8 (16)             |         |
| Coagulase-negative Staphylococci        | 19 (12)             | 6 (12)             |         |
| Streptococci                            | 46 (29)             | 26 (51)            | .004    |
| Enterococci                             | 35 (22)             | 2 (3.9)            | .003    |
| Culture-negative                        | 16 (10)             | 4 (7.8)            | .638    |
| Fungal                                  | 3 (5.1)             | 1 (2.0)            | .973    |
| Others*                                 | 8 (5.0)             | 4 (7.8)            | .452    |
| Aortic insufficiency, n (%)             |                     |                    | .694    |
| Moderate                                | 24 (15)             | 6 (12)             |         |
| Severe                                  | 102 (64)            | 36 (71)            |         |
| Aortic stenosis, n (%)                  | 52 (33)             | 27 (53)            | .009    |
| Calcified valve leaflets, n (%)         | 17 (11)             | 15 (29)            | .001    |
| Root aneurysm, n (%)                    | 2 (1.3)             | 0 (0)              | 1.000   |
| Ascending aneurysm, n (%)               | 6 (3.8)             | 7 (14)             | .010    |
| Status, n (%)                           |                     |                    | .133    |
| Elective                                | 6 (3.8)             | 2 (3.9)            |         |
| Urgent                                  | 129 (81)            | 35 (69)            |         |
| Emergent                                | 24 (15)             | 14 (27)            |         |
| Incidence, n (%)                        |                     |                    | .413    |
| First cardiac surgery                   | 140 (88)            | 47 (92)            |         |
| Reoperation                             | 19 (12)             | 4 (7.8)            |         |
| CPB time, min, median (IQR)             | 184 (138-242)       | 197 (151-265)      | .105    |
| Cross-clamp time, min, median (IQR)     | 146 (107-190)       | 159 (118-205)      | .149    |
| Aortic valve repair, n (%)              | 4 (2.4)             | 1 (2.0)            | .821    |
| AVR, n (%)                              | 75 (47)             | 25 (49)            | .818    |
| Root replacement, n (%)                 | 84 (53)             | 26 (51)            | .818    |
| Prosthetic aortic valve size, mm, median (IQR) | 25 (23-26)         | 26 (25-27)         | .0002   |
| Prostheses used, n (%)                  |                     |                    | .163    |
| Bioprosthesis                           | 148 (93)            | 44 (86)            |         |
| Stentless valve                         | 67 (42)             | 21 (41)            |         |
| Stented valve                           | 65 (44)             | 18 (35)            |         |
| Homograft                               | 16 (10)             | 5 (12)             |         |
| Mechanical valve                        | 7 (4.8)             | 6 (12)             |         |
| CABG, n (%)                             | 17 (11)             | 4 (7.8)            | .384    |
| Mitral valve procedure, n (%)           |                     |                    | .113    |
| Repair                                  | 49 (31)             | 11 (22)            |         |
| Replacement                             | 20 (13)             | 3 (5.9)            |         |

(Continued)

TABLE 2. Continued

| Variable                                | TAV group (N = 159) | BAV group (N = 51) | P value |
|-----------------------------------------|---------------------|--------------------|---------|
| Tricuspid valve procedure, n (%)        |                     |                    | .107    |
| Repair                                  | 27 (17)             | 3 (5.9)            |         |
| Replacement                             | 1 (0.6)             | 0 (0)              |         |
| Ascending procedure                     | 17 (11)             | 10 (20)            | .098    |

Significant P values are in bold type. TAV, Tricuspid aortic valve; BAV, bicuspid aortic valve; CPB, cardiopulmonary bypass; IQR, interquartile range; AVR, aortic valve replacement; CABG, coronary artery bypass grafting. *Organisms with positive blood cultures not otherwise categorized.

much younger average age than those with TAV (42 years [IQR, 30-56 years] vs 54 years [IQR, 44-65 years]; P < .0001). Patients with BAV also had lower rates of coronary artery disease (9.8% vs 22%; P = .05), hypertension (39% vs 58%; P = .02), and congestive heart failure (41% vs 59%; P = .03). There were no significant between-group differences in cases of diabetes, lung disease, pneumonia, or IV drug use (Table 1).

There was no change in the proportions of BAV IE and TAV IE treated at our institution after 2007, when the American Heart Association changed antibiotic prophylaxis guidelines for patients with BAV (25% BAV IE and 75% TAV IE pre-2008 vs 24% BAV IE and 76% TAV IE in 2008-2017; P = .91) (Figure 1).

Intraoperative Results

*Streptococcus* species were more often the causative organism of IE in patients with BAV (51% vs 29% for the TAV group; P = .004), whereas *Enterococcus* species were more often the causative organism in patients with TAV (22% vs 3.9% in the BAV group; P = .003). Patients with BAV had a higher rate of aortic stenosis compared with patients with TAV (53% vs 33%; P = .009). They also had larger prosthetic aortic valves implanted (average size, 26 mm [IQR, 25-27 mm] vs 25 mm [IQR, 23-26 mm]; P = .0002). The BAV group had higher proportions of calcified aortic valve leaflets (29% vs 11%; P = .001) and ascending aneurysms (14% vs 3.8%; P = .02), and a greater percentage of patients with BAV underwent emergent operations for IE (27% vs 15%; P = .05) (Table 2).

Operative Results

There were no significant differences in operative mortality (2.0% for BAV vs 5.0% for TAV) or most postoperative complications (including stroke, sepsis, and new-onset renal failure requiring dialysis) or mortality between the BAV and TAV groups. Significant risk factors for operative mortality identified on multivariable logistic analysis included preoperative liver disease (OR, 13; 95% CI, 3.4-30; P < .0001) (Table 3).
Long-Term Outcomes

The median follow-up for death was 3.7 years (95% CI, 1.6-7.3 years). Completeness of follow up for survival was 100% with national death index data and medical chart review. The long-term survival was significantly greater in patients with BA V compared with patients with TA V (10-year survival, 63.8% vs 45.5%; \( P = .019 \)) (Figure 2). The presence of IV drug use was a significant risk factor for long-term mortality (HR, 4.5; 95% CI, 2.3-8.6; \( P < .0001 \)), as was congestive heart failure (HR, 1.7; 95% CI, 1.0-2.8; \( P = .04 \)), liver disease (HR, 2.6; 95% CI, 1.2-5.7; \( P = .02 \)), and preoperative renal failure requiring dialysis (HR, 4.1; 95% CI, 2.5-6.8; \( P < .0001 \)). The HR of BAV versus TAV was 0.67 (95% CI, 0.3-1.4; \( P = .26 \)) (Table 4).

The median follow-up time for reoperation was 3.6 years (95% CI, 1.5-7.2 years). The percentage completion of follow-up for reoperation was 94%. The 10-year postoperative cumulative incidence of reoperation was significantly higher in the BAV group compared with the TAV group (5.7% vs 4.5%; \( P = .045 \)) (Figure 3). The HR of BAV for reoperation was 2.4 (95% CI, 0.8-7.1; \( P = .11 \)). A total of 15 patients required reoperation. Recurrent endocarditis (50%) and valve deterioration (50%) were the most common indications for reoperation in the patients with TAV, and valve deterioration (86%) was the most common indication in the patients with BAV.

DISCUSSION

In this study, we found that patients with BAV and TAV had similar operative outcomes with acceptable operative mortality. Preoperative liver disease was a significant risk factor for operative mortality (Table 3). IV drug use, preoperative liver disease, congestive heart failure, and preoperative renal failure requiring dialysis were risk factors for long-term mortality (Table 4). Long-term survival was significantly greater in the BAV group compared with the TAV group (10-year survival, 64% vs 46%) (Figure 2), but the BAV group had a higher cumulative incidence of reoperation at 10 years postoperatively (Figure 3).

Although only 2% of the population has a BAV, we found that 24% of patients with IE had BAV. This finding is consistent with other studies.6-8 The disproportionate incidence of IE in patients with BAV is observed despite significantly fewer preoperative risk factors relative to those with TAV IE, such as previous cardiac surgery, a well-known risk factor for IE.9-11 We found that patients with TAV had significantly higher rates of hypertension, coronary artery disease, and congestive heart failure (Table 1). In contrast to patients with TAV IE, patients

| TABLE 3. Univariate logistic regression analysis of operative mortality |
|--------------------------|-----|-----------------|-----------|
| Variable                | OR  | 95% Wald CI     | P value   |
| BAV                     | 0.53| 0.09-3.16       | .49       |
| Liver disease           | 13.0| 3.34-30.3       | <.0001    |
| Emergent status         | 2.54| 0.65-9.92       | .18       |

OR, Odds ratio; CI, confidence interval; BAV, bicuspid aortic valve.

232 JTCVS Open • December 2021
with BAV IE were relatively healthier and younger, and surgical intervention for IE was more likely to be their first cardiac surgery. Several other studies have reported similar results.12-14 These results suggest that there are other reasons for the discrepancy in the incidence of IE in BAV and TAV populations.

Our results demonstrate that patients with BAV were significantly more likely to have calcified aortic valve leaflets or aortic stenosis at the time of operation. This is not surprising, because aortic stenosis is considered the most common complication of BAV.15 Patients with BAV have previously been shown to have earlier onset of valve thickening and a higher incidence of aortic stenosis compared with the general population.16 The underlying pathophysiology is thought to be related to the abnormal shear stress of turbulent blood flow across bicuspid valves, which over time may lead to endocardial tissue damage, fibrosis, and subsequent valve calcification, which can increase the likelihood of formation of infectious vegetation on valves.11,16-18 The severe calcification could be one reason why native BAV may be more susceptible to bacterial infection and help explain our findings in the BAV group. In addition, we found that a greater proportion of patients with BAV had an ascending aortic aneurysm or severe aortic insufficiency (AI) at the time of operation compared with patients with TAV. The AI may be related to the annular dilation and the prolapse of the BAV, which therefore also increases the susceptibility of BAVs to bacterial infection.19,20 Furthermore, there is growing evidence of genetically-weaker aortic walls in patients with BAV, with studies noting decreased aortic fibrillin, elastin fragmentation, increased smooth muscle cell apoptosis, aortic extracellular matrix degeneration, and cystic medial necrosis patients with BAV.20-25 These genetic abnormalities further increase the risk of developing ascending aortic aneurysms, AI, and subsequent IE. For patients with BAV, the combination of turbulent blood flow through the BAV, greater leaflet calcification, and increased rates of ascending aortic aneurysm and AI may contribute to their increased susceptibility to IE. Owing to this damage to the BAV from valvulopathy and hemodynamics, patients with BAV may be more susceptible to oral bacterial flora such as

### TABLE 4. Cox proportional hazards regression for long-term mortality

| Variable                        | HR   | 95% CI      | P value |
|---------------------------------|------|-------------|---------|
| Bicuspid aortic valve           | 0.67 | 0.33-1.4    | .26     |
| Age                             | 1.0  | 1.0-1.0     | .06     |
| Female sex                      | 0.97 | 0.6-1.6     | .89     |
| Intravenous drug abuse          | 4.5  | 2.3-8.6     | <.0001  |
| Coronary artery disease         | 1.2  | 0.68-2.2    | .50     |
| Cardiogenic shock               | 1.2  | 0.5-2.7     | .65     |
| Congestive heart failure        | 1.7  | 1.0-2.8     | .04     |
| Preoperative sepsis             | 0.55 | 0.26-1.2    | .12     |
| Liver disease                   | 2.6  | 1.2-5.7     | .02     |
| Preoperative renal failure      | 4.1  | 2.5-6.8     | <.0001  |

Significant P values are in bold type. Age violated the PH assumption as a continuous variable, so it was modeled as a binary variable (≥60 vs <60). HR, Hazard ratio; CI, confidence interval.

![Cumulative incidence of reoperation in patients with surgical infective endocarditis (IE) in the bicuspid aortic valve (BAV) group and tricuspid aortic valve (TAV) group. The 15-year incidence of reoperation was 17.9% (95% confidence interval [CI], 6.0%-35%) in the BAV group and 7.70% (95% CI, 3.1%-24%) in the TAV group.](image-url)
5-year and 10-year survival rates (Figure 2). This trend is likely or postoperative complications between the patients with BAV and those with TAV (Table 5). Even though the patients with BAV were at greater risk for developing IE at an earlier age and with fewer comorbidities, Kaplan-Meier analysis demonstrated a significantly greater long-term survival rate in these patients compared with patients with TAV IE (Figure 2). Although other studies have demonstrated similar significant differences in long-term survival, they were often limited by shorter follow-up periods—typically between 1 and 5 years. We also observed a significantly different cumulative incidence of reoperation at 15 years, with 17.9% for BAV IE versus 7.7% for TAV IE ($P = .0454$) (Figure 3). Although few other studies have reported reoperation rates for patients with BAV IE, our results are similar to Goland and colleagues’ finding of a 7.1% reoperation rate for BAV IE repair after a follow-up of 15 years. Interestingly, although recurrent IE was the indicated reason for the majority of TAV IE reoperations, recurrent IE was not the indication for reoperation in any patients in the BAV IE group. This finding identifies the native diseased valve as a risk factor for IE in patients with BAV. After replacement of the diseased BAV, the rate of recurrent endocarditis decreased. However, those patients still underwent reoperation owing to structural deterioration of the bioprosthesis.

Interestingly, the BAV IE group had significantly more cases of *Streptococcus* IE than the TAV IE group, but better 5-year and 10-year survival rates (Figure 2). This trend is supported by the finding that although *Streptococcus* species infections are associated with dental procedures and poor oral hygiene, *Streptococcus* IE has been associated with lower risk of mortality in the intensive care unit and better overall outcomes. Furthermore, recent studies have suggested that dental procedure-induced IE in patients with BAV is less common than previously thought. Poor oral hygiene is another important contributor to the development of IE. This suggests that greater emphasis should be placed on proper oral hygiene practices and routine dental follow-up for IE risk mitigation instead of antibiotic prophylaxis.

Despite our findings, other methods of IE prevention are still warranted. Kiyota and colleagues described how a majority of patients with BAV were unaware of their condition until the onset of a major morbidity. Tribouilloy and colleagues noted that in 92% of their patients with BAV IE, the presence of BAV was not discovered until IE was diagnosed. Considering the mounting evidence that those with BAVs are at greater risk of developing IE despite being younger and having fewer comorbidities than those with TAVs, it is important to identify patients with BAV early. As such, earlier identification of BAVs allows for earlier patient education regarding the importance of maintaining proper oral hygiene and routine dental follow-up. At our institution, all family members of BAV patients are advised to undergo echocardiography, and patients with detected murmurs could also undergo echocardiography for earlier identification of BAV. We recommend screening as early as possible.

### Table 5. Postoperative data

| Variable                                      | TAV group (N = 159) | BAV group (N = 51) | $P$ value |
|-----------------------------------------------|---------------------|--------------------|-----------|
| Red blood cell units infused, median (IQR)    | 3.0 (1.0-5.0)       | 2.0 (0.0-4.0)      | .160      |
| Reoperation for bleeding, n (%)               | 7 (4.4)             | 1 (2.0)            | .683      |
| Planned delayed closure, n (%)                | 1 (0.6)             | 0 (0)              | 1.000     |
| Sternal dehiscence, n (%)                     | 0 (0)               | 0 (0)              | 1.000     |
| Sepsis, n (%)                                 | 4 (2.5)             | 1 (2.0)            | 1.000     |
| Stroke, n (%)                                 | 1 (0.6)             | 2 (3.9)            | .146      |
| ICU stay, d median (IQR)                      | 2.3 (0.0-6.1)       | 1.2 (0.0-4.0)      | .178      |
| Duration of ventilation, h, median (IQR)      | 11 (2.4-24)         | 5.4 (1.9-22)       | .290      |
| Pneumonia, n (%)                              | 8 (5.0)             | 2 (3.9)            | 1.000     |
| Cardiac arrest, n (%)                         | 5 (3.1)             | 0 (0)              | .339      |
| Device, n (%)                                 |                     |                    |           |
| Pacemaker                                     | 9 (5.7)             | 2 (3.9)            | .526      |
| ICD                                           | 1 (0.6)             | 0 (0)              |           |
| New-onset renal failure on dialysis, n (%)    | 11 (7.1)            | 2 (4.0)            | .738      |
| Multisystem organ failure, n (%)              | 1 (0.6)             | 0 (0)              | 1.000     |
| Gastrointestinal event, n (%)                 | 13 (8.2)            | 5 (9.8)            | .718      |
| Atrial fibrillation, n (%)                    | 44 (28)             | 8 (16)             | .084      |
| Intraoperative mortality, n (%)               | 3 (1.9)             | 0 (0)              | 1.000     |
| In-hospital mortality, n (%)                  | 7 (4.4)             | 1 (2.0)            | .683      |
| 30-d mortality, n (%)                         | 8 (5.0)             | 1 (2.0)            | .691      |
| Operative mortality, n (%)                   | 8 (5.0)             | 1 (2.0)            | .691      |

TAV, Tricuspid aortic valve; BAV, bicuspid aortic valve; IQR, interquartile range; ICU, intensive care unit; ICD, implantable cardioverter defibrillator. *Operative mortality is based on the Society of Thoracic Surgeons definition and includes all deaths, regardless of cause, occurring during the hospitilization in which the operation was performed, even if after 30 days (including patients transferred to other acute care facilities); and all deaths, regardless of cause, occurring after discharge from the hospital, but before the thirtieth postoperative day.
as possible in childhood, because BAV is a congenital defect. The pediatrician and cardiologist can detect BAV with a heart murmur on physical examination, especially in patients with a family history of BAV. In patients with BAV, scrupulous oral hygiene is advised.

Study Limitations

This is a single-center, retrospective study and thus is of limited breadth. The cases of IE included only surgical IE cases, and the BAV IE sample size was relatively small. The significant difference in age between the 2 groups might have had a significant impact on difference in long-term surgical outcomes, although age was not identified as a significant risk factor for mortality in our multivariable analysis. Our short-term mortality is also limited by the possibility of a type II error. Our follow-up for reoperation was 94%, which could have slightly underestimated our rate of reoperation. The cause-specific hazard model was limited in lacking the inclusion of all potential confounders given data limitations. The 20-year span of our study also could have limited the homogeneity of our results; however, the majority of cases of aortic valve IE were treated by the same aortic surgeons, and surgical techniques remained similar since the initiation of data collection.

CONCLUSIONS

Compared with patients with a TAV, patients with a BAV developed IE at a younger age and with fewer comorbidities, and had better long-term survival after surgical treatment (Figure 4). Early detection of a BAV condition is important to prevent IE and provide aggressive surgical treatment should IE occur (Video 1).

Conflict of Interest Statement

Dr Patel reported financial relationships with Medtronic, WL Gore, and Edwards Lifesciences. Dr Deeb reported a financial relationship with Medtronic. All other authors reported no conflicts of interest.
The *Journal* policy requires editors and reviewers to disclose conflicts of interest and to decline handling or reviewing manuscripts for which they may have a conflict of interest. The editors and reviewers of this article have no conflicts of interest.

References

1. Ward C. Clinical significance of the bicuspid aortic valve. *Heart*. 2000;83:81-5.
2. Miledelina HL, Katon O, Suri RM, Baddour LM, Enriquez-Sarano M. Incidence of infective endocarditis in patients with bicuspid aortic valve in the community. *Mayo Clin Proc*. 2016;91:122-3.
3. Centers for Disease Control and Prevention. National death index. Available at: https://www.cdc.gov/nchs/ndi/index.htm. Accessed June 30, 2020.
4. Clark TG, Altman DG, De Stavola BL. Quantification of the completeness of follow-up. *Lancet*. 2002;359:1309-10.
5. Yang B, Caceres J, Farhat L, Le T, Brown B, St Pierre E, et al. Root abscess in the setting of infectious endocarditis: short- and long-term outcomes. *J Thorac Cardiovasc Surg*. 2021;162:1049-59.e1.
6. Lamas CC, Eykyn SJ. Bicuspid aortic valve—a silent danger: analysis of 50 cases of infective endocarditis. *Clin Infect Dis*. 2000;30:336-41.
7. Chen J, Lu S, Hu K, Yang Z, Pan S, Hong T, et al. Clinical characteristics and surgical treatment of infective endocarditis with bicuspid aortic valve. *Int Heart J*. 2017;58:220-4.
8. Kyota Y, Della Corte A, Monterio Vieira V, Habchi K, Huang CC, Della Ratta EE, et al. Risk and outcomes of aortic valve endocarditis among patients with bicuspid and tricuspid aortic valves. *Open Heart*. 2017;4:e000545.
9. Pans A, Patel NJ, Dumitru M, Golwala H, Patel N, Badhika A, et al. Trends in infective endocarditis incidence, microbiology, and valve replacement in the United States from 2000 to 2011. *J Am Coll Cardiol*. 2015;65:2070-6.
10. Goyal A, Chhabra L, Gupta R, Khalid N. Minimally invasive aortic valve surgery. *Mayo Clin Proc*. 2016;91:122-3.
11. McDonald JR. Acute infective endocarditis. *Infect Dis Clin North Am*. 2009;23:643-64.
12. Tribouilloy C, Rasidman D, Sorel C, Thuny F, Casalta JP, Riberi A, et al. Clinical characteristics and outcome of infective endocarditis in adults with bicuspid aortic valves: a multicentre observational study. *Heart*. 2010;96:1723-9.
13. Becerra-Muñoz VM, Ruiz-Morales J, Rodríguez-Bailón I, Sánchez-Espin G, López-Garrido MA, Robledo-Carmona J, et al. Infective endocarditis in patients with bicuspid aortic valve: clinical characteristics, complications, and prognosis. *Infect Inf Immuno*. 2017;85:649-56.
14. Khabecchi G, Bayrak F, Pala S, Mutlu B. Impact of bicuspid aortic valve on complications and death in infective endocarditis of native aortic valves. *Tex Heart Inst J*. 2009;36:111-6.
15. Roberts WC, McCullough SP, Vasudevan A. Characteristics of adults having aortic valve replacement for pure aortic regurgitation involving a congenitally bicuspid aortic valve unaffected by infective endocarditis or aortic dissection. *Am J Cardiol*. 2018;122:2104-11.
16. Campbell M. Calcific aortic stenosis and congenital bicuspid aortic valves. *Br Heart J*. 1968;30:666-16.
17. Campbell M. The natural history of congenital aortic stenosis. *Br Heart J*. 1968;30:514-26.
18. Robicsek F, Thubrikar MJ, Cook JW, Fowler B. The congenitally bicuspid aortic valve: how does it function? Why does it fail? *Ann Thorac Surg*. 2004;77:171-85.
19. Roach MR. Changes in arterial distensibility as a cause of poststenotic dilatation. *Am J Cardiol*. 1963;12:802-15.
20. Hahn RT, Roman MJ, Møggaard AH, Devereux RB. Association of aortic dilation with regurgitant, stenotic and functionally normal bicuspid aortic valves. *J Am Coll Cardiol*. 1992;19:283-8.
21. Gurvitz M, Chang RK, Drant S, Allada V. Frequency of aortic root dilation in children with a bicuspid aortic valve. *Am J Cardiol*. 2004;94:1337-40.
22. de Sa M, Moshkovitz Y, Butany J, David TE. Histologic abnormalities of the ascending aorta and pulmonary trunk in patients with bicuspid aortic valve disease: clinical relevance to the Ross procedure. *J Thorac Cardiovasc Surg*. 1999;118:588-94.
23. Fedak PWM, de Sa MPL, Verma S, Nili N, Kazemian P, Butany J, et al. Vascular matrix remodeling in patients with bicuspid aortic valve malformations: implications for aortic dilatation. *J Thorac Cardiovasc Surg*. 2003;126:797-806.
24. Cotrufo M, Della Corte A, De Santo LS, Quarto C, De Feo M, Romano G, et al. Different patterns of extracellular matrix protein expression in the convexity and the concavity of the dilated aorta with bicuspid aortic valve: preliminary results. *J Thorac Cardiovasc Surg*. 2005;130:504-11.
25. Ikonomidis JS, Jones JA, Barbour JR, Stroud RE, Clark LL, Kaplan BS, et al. Expression of matrix metalloproteinases and endogeous inhibitors within ascending aortic aneurysms of patients with bicuspid or tricuspid aortic valves. *J Thorac Cardiovasc Surg*. 2007;133:1028-36.
26. Golland S, Czer LSC, De Roberts MA, Mirocha J, Kass RM, Fontana GP, et al. Risk factors associated with reoperation and mortality in 252 patients after aortic valve replacement for congenitally bicuspid aortic valve disease. *Ann Thorac Surg*. 2007;83:931-7.
27. Joffre I, Dumas G, Aegerter P, Dubé V, Bigé N, Preda G, et al. Epidemiology of infective endocarditis in French intensive care units over the 1997-2014 period from the CUB-Réa network. *Crit Care*. 2019;23:143.
28. Long B, Koryfman A. Infectious endocarditis: an update for emergency clinicians. *Am J Emerg Med*. 2018;36:1686-92.
29. Lockhart PB, Brennan MT, Thornhill M, Michalowicz BS, Noll J, Bahrami-Mougeot FK, et al. Poor oral hygiene as a risk factor for infective endocarditis-related bacteremia. *J Am Dent Assoc*. 2009;140:1238-44.
30. Lockhart PB. Antibiotic prophylaxis for dental procedures: are we drilling in the wrong direction? *Circulation*. 2012;126:11-2.
31. Baddour LM, Wilson WR, Bayer AS, Fowler VG Jr, Tleyjeh IM, Rybak MJ, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. *Circulation*. 2015;132:1435-86.

**Key Words:** bicuspid aortic valve, aortic valve, endocarditis, aortic valve replacement, reoperation, survival.